Australia’s James McFadyen and Hannah Stevens join the podcast to reveal their latest research on immunothrombosis and monoclonal antibody therapies. They are developing novel platelet targeted therapies for the treatment of thrombosis and immunothrombosis, and recently their team is using omics and large datasets for VTE risk prediction. Learn the full scope of their research, from utilizing AI in their work, to how the research results will help improve thrombosis treatment in the future.